First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Authors: Yuankai Shi, L. Wang, Baohui Han, W. Li, Pei-wu Yu, Y.P. Liu, Chunming Ding, Xia Song, Z.Y. Ma, Xiaowen Ren, J. Feng, H. L. Zhang, G. -Y. Chen, Xiaohong Han, Ning Wu, Chia-Yu Yao, Yong Song, S. C. Zhang, Wei Song, X. Q. Liu, Sha Zhao, Yangxuan Lin, X.Q. Ye, K. Li, Yongqian Shu, Lili Ding, F. Tan, Yan Sun - Annals of Oncology 2017 cited by 338